More comorbidities in acromegaly patients without biochemical control
Acromegaly patients with poor biochemical control have more comorbidities than their counterparts with good biochemical control, a new study reveals.
Of 121 included acromegaly patients (mean age 55.4±16.7 years; 55 percent male), 120 had insulin-like growth factor-I (IGF-1) values reported. Over the mean study period of 8.8 years, biochemical control was achieved in 65.8 percent (n=79) and not achieved in 34.2 percent (n=41).
New cases of hypertension and diabetes were recorded in 7.6 (n=6) and 3.8 (n=3) percent of controlled patients, respectively, and in 7.3 (n=3) and 9.8 (n=4) percent of uncontrolled patients, respectively.
New left ventricular hypertrophy (LVH) was observed in 8.9 (n=7) and 4.9 (n=2) percent of controlled and uncontrolled patients, respectively. No new cases of heart failure were reported.
Considering comorbidities observed at any time during care, hypertension and diabetes were observed in 41.8 (n=33) and 25.3 (n=20) percent of the controlled group and in 58.5 (n=24) and 41.5 (n=17) percent of the uncontrolled group.
Moreover, LVH was present in 11.4 percent (n=9) of controlled patients and in and 9.8 percent (n=4) uncontrolled patients, while heart failure was observed in 3.8 (n=3) and 7.3 (n=3) percent, respectively.
At baseline, mean IGF-1 levels were 260 percent of the upper limit of normal (ULN) in patients who later achieved biochemical control; mean last IGF-1 in these patients was 67.7 percent ULN. In those who did not achieve control, mean baseline and last IGF-1 measurements were 242 and 177.8 percent ULN, respectively.
Biochemical control was defined as having a last IGF-1 measurement of less than or equal to the ULN for the specific patient’s age and gender. Primary and secondary outcomes of the study were new onset comorbidities and comorbidities at any time during the study period, respectively.